Triple
T17262095
| Position | Surface form | Disambiguated ID | Type / Status |
|---|---|---|---|
| Subject | Biota Holdings |
E419031
|
entity |
| Predicate | hasSuccessor |
P78
|
FINISHED |
| Object |
Biota Pharmaceuticals
Biota Pharmaceuticals was an Australian biotechnology company focused on developing antiviral therapies, particularly for respiratory and infectious diseases.
|
E419031
|
NE FINISHED |
How this triple was built (4 steps)
Every LLM step that produced this triple, in pipeline order — named-entity classification, the disambiguation choices (the exact options shown, with the pick highlighted), and the generated description. The batch + timestamp of each is in the Provenance table below.
NER
Named-entity recognition
gpt-5-mini
Instruction
Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).
Input
Phrase: Biota Pharmaceuticals | Statement: [Biota Holdings, hasSuccessor, Biota Pharmaceuticals]
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: Biota Pharmaceuticals Context triple: [Biota Holdings, hasSuccessor, Biota Pharmaceuticals]
-
A.
Biota Holdings
Biota Holdings is an Australian biotechnology company best known for discovering and developing antiviral drugs, including the influenza medication zanamivir.
-
B.
Array BioPharma
Array BioPharma is a biopharmaceutical company known for developing targeted small-molecule cancer therapies, particularly in oncology and rare diseases.
-
C.
Portola Pharmaceuticals
Portola Pharmaceuticals is a biopharmaceutical company specializing in the development of therapies for thrombosis and other hematologic conditions.
-
D.
Nautilus Biotechnology
Nautilus Biotechnology is a life sciences company developing next-generation, high-throughput proteomics platforms to enable comprehensive analysis of the human proteome for research and drug discovery.
-
E.
Hargreave-Rasch Biotechnologies
Hargreave-Rasch Biotechnologies is a fictional advanced biotech corporation in the Crysis video game universe, known for its cutting-edge research into alien technology and military applications.
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NEDg
Description generation
gpt-5.1
Instruction
Generate a one-sentence description of the target entity. You are given a context triple in the form (subject, predicate, object), where the object is the target entity. # Instructions Use the triple to infer relevant information about the entity. Describe the entity based on what is most defining, well-known. Avoid repeating the information from the triple, unless really essential. # Response Format Return only the sentence: "Description: [one-sentence description of the target entity]"
Input
Entity: Biota Pharmaceuticals Triple: [Biota Holdings, hasSuccessor, Biota Pharmaceuticals]
Generated description
Biota Pharmaceuticals was an Australian biotechnology company focused on developing antiviral therapies, particularly for respiratory and infectious diseases.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: Biota Pharmaceuticals Target entity description: Biota Pharmaceuticals was an Australian biotechnology company focused on developing antiviral therapies, particularly for respiratory and infectious diseases.
-
A.
Biota Holdings
chosen
Biota Holdings is an Australian biotechnology company best known for discovering and developing antiviral drugs, including the influenza medication zanamivir.
-
B.
Array BioPharma
Array BioPharma is a biopharmaceutical company known for developing targeted small-molecule cancer therapies, particularly in oncology and rare diseases.
-
C.
Portola Pharmaceuticals
Portola Pharmaceuticals is a biopharmaceutical company specializing in the development of therapies for thrombosis and other hematologic conditions.
-
D.
Nautilus Biotechnology
Nautilus Biotechnology is a life sciences company developing next-generation, high-throughput proteomics platforms to enable comprehensive analysis of the human proteome for research and drug discovery.
-
E.
Hargreave-Rasch Biotechnologies
Hargreave-Rasch Biotechnologies is a fictional advanced biotech corporation in the Crysis video game universe, known for its cutting-edge research into alien technology and military applications.
- F. None of above.
Provenance (5 batches)
The batch behind each pipeline step, in order, with when it ran. Timestamps are batch-level — stages were processed in waves, so the object chain (NER → NED1 → NEDg → NED2) reads in order, but predicate / elicitation batches can sit in a different wave.
| Step | Stage | Batch ID | Status | When |
|---|---|---|---|---|
| creating | Elicitation | batch_69d886d9ab108190b70edd8d17aa1204 |
completed | April 10, 2026, 5:12 a.m. |
| NER | Named-entity recognition | batch_69e42e717a348190ae6835fb08f38125 |
completed | April 19, 2026, 1:22 a.m. |
| NED1 | Entity disambiguation (via context triple) | batch_6a0171041f2c81909bf52025d68912fc |
completed | May 11, 2026, 6:02 a.m. |
| NEDg | Description generation | batch_6a0171c1b5fc81908455cda0df277ea9 |
completed | May 11, 2026, 6:05 a.m. |
| NED2 | Entity disambiguation (via description) | batch_6a01724c4e34819099168d7303a31498 |
completed | May 11, 2026, 6:08 a.m. |
Created at: April 10, 2026, 5:39 a.m.